Repository logo
 

CCT complex restricts neuropathogenic protein aggregation via autophagy

Published version
Peer-reviewed

Change log

Abstract

Aberrant protein aggregation is controlled by various chaperones, including CCT (chaperonin containing TCP-1)/TCP-1/TRiC. Mutated CCT4/5 subunits cause sensory neuropathy and CCT5 expression is decreased in Alzheimer's disease. Here, we show that CCT integrity is essential for autophagosome degradation in cells or Drosophila and this phenomenon is orchestrated by the actin cytoskeleton. When autophagic flux is reduced by compromise of individual CCT subunits, various disease-relevant autophagy substrates accumulate and aggregate. The aggregation of proteins like mutant huntingtin, ATXN3 or p62 after CCT2/5/7 depletion is predominantly autophagy dependent, and does not further increase with CCT knockdown in autophagy-defective cells/organisms, implying surprisingly that the effect of loss-of-CCT activity on mutant ATXN3 or huntingtin oligomerization/aggregation is primarily a consequence of autophagy inhibition rather than loss of physiological anti-aggregation activity for these proteins. Thus, our findings reveal an essential partnership between two key components of the proteostasis network and implicate autophagy defects in diseases with compromised CCT complex activity.

Description

Journal Title

Nature Communications

Conference Name

Journal ISSN

2041-1723
2041-1723

Volume Title

7

Publisher

Nature Publishing Group

Rights and licensing

Except where otherwised noted, this item's license is described as Attribution 4.0 International
Sponsorship
Wellcome Trust (095317/Z/11/A)
Wellcome Trust (095317/Z/11/Z)
European Commission (264508)
Cambridge University Hospitals NHS Foundation Trust (CUH) (unknown)
Wellcome Trust (100140/Z/12/Z)
Alzheimer's Research Trust (ART-SRF2010-2)
Medical Research Council (MC_G1000734)
We are grateful to the Wellcome Trust (Principal Research Fellowship to DCR (095317/Z/11/Z)), a Strategic Grant to Cambridge Institute for Medical Research (100140/Z/12/Z), NIHR Biomedical Research Unit in Dementia at Addenbrooke’s Hospital, the Treat PolyQ project (European community’s Seventh Framework Programme under grant agreement No 264508) and the Wellcome Trust/MRC strategic grant for neurodegeneration (D.C.R. and C.J.O.'K.) for funding. DCC was supported by an Alzheimer’s Research U.K. Senior Research Fellowship (ART-SRF2010-2) and by the Wellcome Trust (082604/2/07/Z).